Repurposing sunscreen as an antibiotic: zinc-activated avobenzone inhibits methicillin-resistant Staphylococcus aureus
Metallomics · 2023
DOI: 10.1093/mtomcs/mfad049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metallomics, 2023. Verfasst von Rachel M Andrews und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA) is a major healthcare concern with associated healthcare costs reaching over ${\$}$1 billion in a single year in the USA. Antibiotic resistance in S. aureus is now observed against last line of defense antibiotics, such as vancomycin, linezolid, and daptomycin. Unfortunately, high throughput drug discovery approaches to identify new antibiotics effective against MRSA have not resulted in much tangible success over the last decades. Previously, we demonstrated the feasibility of an alternative drug discovery approach, the identification of metallo-antibiotics, compounds that gain antibacterial activity only after binding to a transition metal ion and as such are unlikely to be detected in standard drug screens. We now report that avobenzone, the primary active ingredient of most sunscreens, can be activated by zinc to become a potent antibacterial compound against MRSA. Zinc-activated avobenzone (AVB-Zn) potently inhibited a series of clinical MRSA isolates [minimal inhibitory concentration (MIC): 0.62–2.5 µM], without pre-existing resistance and activity without zinc (MIC: >10 µM). AVB-Zn was also active against clinical MRSA isolates that were resistant against the commonly used zinc–salt antibiotic bacitracin. We found AVB-Zn exerted no cytotoxicity on human cell lines and primary cells. Last, we demonstrate AVB-Zn can be deployed therapeutically as lotion preparations, which showed efficacy in a mouse wound model of MRSA infection. AVB-Zn thus demonstrates Zn-activated metallo-antibiotics are a promising avenue for future drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Chemistry, Kansas State University, Kansas City, KS, USA.
- Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS, USA.
ORCID-Profile: Rachel M Andrews
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Andrews, R. M., Bollar, G. E., Giattina, A. S., Dalecki, A. G., Wallace, J. R., Frantz, L., Eschliman, K., Covarrubias-Zambrano, O., Keith, J. D., Duverger, A., Wagner, F., Wolschendorf, F., Bossmann, S. H., Birket, S. E., & Kutsch, O. (2023). Repurposing sunscreen as an antibiotic: zinc-activated avobenzone inhibits methicillin-resistant Staphylococcus aureus. Metallomics. https://doi.org/10.1093/mtomcs/mfad049
Vancouver
Andrews RM, Bollar GE, Giattina AS, Dalecki AG, Wallace JR, Frantz L, et al. Repurposing sunscreen as an antibiotic: zinc-activated avobenzone inhibits methicillin-resistant Staphylococcus aureus. Metallomics. 2023. doi:10.1093/mtomcs/mfad049
BibTeX
@article{Andrews2023,
author = {Andrews, Rachel M and Bollar, Gretchen E and Giattina, A Sophia and Dalecki, Alex G and Wallace, John R and Frantz, Leah and Eschliman, Kayla and Covarrubias-Zambrano, Obdulia and Keith, Johnathan D and Duverger, Alexandra and Wagner, Frederic and Wolschendorf, Frank and Bossmann, Stefan H and Birket, Susan E and Kutsch, Olaf},
title = {Repurposing sunscreen as an antibiotic: zinc-activated avobenzone inhibits methicillin-resistant Staphylococcus aureus},
journal = {Metallomics},
year = {2023},
doi = {10.1093/mtomcs/mfad049}
}
EUVIMED